Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671285 | 0.83 | PLA2G1B (0.35) | PLA2G1BATG4BCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21718845 | 0.76 | PLA2G1B (0.37) | PLA2G1BATG4BNPC1MITFALDH1A1 | |
| SCHEMBL3771478 | 0.74 | MAPT (0.33) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21720617 | 0.74 | CYP1A2 (0.35) | PLA2G1BATG4BALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL14167479 | 0.71 | — | — | |
| SCHEMBL23188723 | 0.71 | TSHR (0.36) | PLA2G1BATG4BNPC1ALDH1A1RAB9A | |
| SCHEMBL15750508 | 0.69 | — | — | |
| SCHEMBL15750488 | 0.69 | RIPK2 (0.36) | PLA2G1BATG4BALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL23400603 | 0.69 | GABRA1 (0.35) | PLA2G1BATG4BNPC1ALDH1A1RAB9A | |
| SCHEMBL15273680 | 0.68 | HPGD (0.38) | NPC1MITFALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952514-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| EP-2632925-B1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2632925-B1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2632925-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012056372-A1 | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | PLA2G1B 2199/4885ATG4B 3102/4885NPC1 175/4885 |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | PLA2G1B 2199/4885ATG4B 3102/4885NPC1 175/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | PLA2G1B 2199/4885ATG4B 3102/4885NPC1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.